European Archives - Page 1108 of 1227 - European Medical Journal

EMJ

New Congress on Thrombosis and Haemostasis

Amsterdam, The Netherlands: The very first ECTH will be held at the World Forum in The Hague, The Netherlands, from 28 – 30 September 2016.

EMJ

MammaPrint Genetic Test Can Reduce Use of Post-Surgery Chemotherapy among Early-Stage Breast Cancer Patients

NEW ORLEANS — Among patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biological…

EMJ

Norgine Expands Its Partnership with Apharm to Commercialise ZIVEREL® in New European Countries

LONDON, 15 April 2015, 07:00 AM BST: Norgine B.V. announced today that it has expanded its agreement with Apharm s.r.l. to distribute ZIVEREL® in…

EMJ

Heart Attack Patients More Depressed but Get Less Antidepressants

Athens, Greece – 16 April 2016: Heart attack patients are more depressed but are less often prescribed antidepressants than people who have not had a…

From Bench to Bedside: Targeting the IL-1β Pathway in Autoinflammatory Diseases

Prof Gerd Horneff opened the symposium with a summary of the recent advances in the understanding of the role of interleukin (IL)-1β in the pathogenesis…

EMJ Rheumatology 3 [Suppl 5] 2016

American College of Rheumatology Association of Rheumatology Health Professionals (ACR/ARHP) 2015 Meeting Highlights: New Data on Canakinumab

EMJ Rheumatology 3 [Suppl 4] 2016

This symposium explored the pathogenesis and treatment approaches for autoinflammatory diseases, including the role of IL-1β and anti-IL-1β therapeutics…

American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) 2015 Meeting Highlights: New Data on Canakinumab

nterleukin (IL)-1 is a messenger for the regulation of inflammatory responses, but it can be harmful when in excess, such as in the inflammation observed…

Treating Active HIDS with Canakinumab

The efficacy and safety of canakinumab in active hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS) and the implications of the results for the future treatment of patients with the condition.

Pathophysiology and Treatment of HIDS

At the American College of Rheumatology Annual Meeting, topic of interest is the pathophysiology and treatment of the condition hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS)